HCPCS Level IIdrugActive
J3391
Inj, atidarsagene autotemcel
BETOS: O1E
Effective: 2025-07-01
Referenced in 1 policies
Description
Injection, atidarsagene autotemcel, per treatment
Medicare Part B Drug Pricing
Average Sales Price (ASP) data for Q1 2026
Drug Name
Lenmeldy
Manufacturer
Orchard Therapeutics Europe Limited
HCPCS Dosage
Per Treatment Dose
Billing Units
1.0000
1
NDC Products
opps
Pricing Source
Medicare Part B drugs are reimbursed at ASP + 6%. Pricing updates quarterly based on manufacturer-reported data.